


Searching News Database: antibody-drug conjugates
HSMN NewsFeed - 19 Feb 2025
Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US
Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US
HSMN NewsFeed - 23 May 2024
SystImmune, Inc. Announces the Appointment of Dr. Jonathan Cheng as New Chief Medical Officer
SystImmune, Inc. Announces the Appointment of Dr. Jonathan Cheng as New Chief Medical Officer
HSMN NewsFeed - 22 Jun 2022
Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer
Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer
HSMN NewsFeed - 29 Jan 2019
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
HSMN NewsFeed - 1 Oct 2018
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
HSMN NewsFeed - 12 Sep 2018
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
HSMN NewsFeed - 24 Jul 2018
Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
HSMN NewsFeed - 24 Apr 2018
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
HSMN NewsFeed - 29 Aug 2017
Sorrento Therapeutics, Inc. Submits NDA For ZTlido(TM) Next-Generation Lidocaine Patch
Sorrento Therapeutics, Inc. Submits NDA For ZTlido(TM) Next-Generation Lidocaine Patch
HSMN NewsFeed - 6 Jan 2015
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
HSMN NewsFeed - 18 Jun 2014
Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer
Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer
HSMN NewsFeed - 9 Jan 2014
Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
HSMN NewsFeed - 8 Jan 2014
Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer
Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer
HSMN NewsFeed - 14 Nov 2013
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
HSMN NewsFeed - 8 Oct 2013
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding
HSMN NewsFeed - 6 Mar 2012
CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors
CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors
HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
HSMN NewsFeed - 27 Mar 2007
Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech
Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech
Additional items found! 11
Members Archive contains
11 additional stories matching:
antibody-drug conjugates
(Password required)
antibody-drug conjugates
(Password required)
